Photopheresis as an Interventional Therapy for the Treatment of CTCL (Cutaneous T-Cell Lymphoma, Mycosis Fungoides) Stage 1A, 1B, 2A

PHASE4CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

April 2, 2004

Primary Completion Date

April 5, 2011

Study Completion Date

April 5, 2011

Conditions
Cutaneous T Cell LymphomaMycosis Fungoides
Interventions
DRUG

Methoxsalen+ECP

UVAdex+ECP will be administered: Treatment consists of two photopheresis treatments on successive days every 4 weeks for six months

Trial Locations (7)

15213

University of Pittsburgh, Pittsburgh

37232

Vanderbilt University Medical Center, Nashville

44106

University Hospital of Cleveland/Case Western Reserve University, Cleveland

55455

University of Minnesota, Minneapolis

60612

Rush-Presbyterian Hospital, Chicago

77030

MD Anderson Cancer Center, Houston

02118

Boston Medical Center, Boston

Sponsors
All Listed Sponsors
collaborator

Boston Medical Center

OTHER

collaborator

University of Pittsburgh

OTHER

collaborator

Case Western Reserve University

OTHER

collaborator

Vanderbilt University Medical Center

OTHER

collaborator

University of Minnesota

OTHER

collaborator

Rush University Medical Center

OTHER

collaborator

Mallinckrodt

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER